Nucala and Hyperventilation - a phase IV clinical study of FDA data

Summary:

Hyperventilation is reported as a side effect among people who take Nucala (mepolizumab), especially for people who are female, 40-49 old, also take Symbicort, and have Asthma.

The phase IV clinical study analyzes which people have Hyperventilation when taking Nucala. It is created by eHealthMe based on reports of 26,865 people who have side effects when taking Nucala from the FDA, and is updated regularly.

What is Nucala?

Nucala has active ingredients of mepolizumab. eHealthMe is studying from 26,883 Nucala users. Check the latest studies of Nucala.

What is Hyperventilation?

Hyperventilation is found to be associated with 846 drugs and 1,433 conditions by eHealthMe. Check the latest studies of Hyperventilation.

On Nov, 28, 2025

26,865 people reported to have side effects when taking Nucala.
Among them, 81 people (0.3%) have Hyperventilation.

Among these 81 people:

What is the gender of people who have Hyperventilation when taking Nucala? *

female: 57.89 %
male: 42.11 %

What is the age of people who have Hyperventilation when taking Nucala? *

What are other drugs people take besides Nucala? *

What are other side effects people have besides Hyperventilation? *

Chest Pain: 79 people, 97.53%
Cough: 79 people, 97.53%
Asthma: 70 people, 86.42%
Wheezing (a high-pitched whistling sound made while you breath): 68 people, 83.95%
Dyspnea (difficult or laboured breathing): 59 people, 72.84%
Nausea (feeling of having an urge to vomit): 47 people, 58.02%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 46 people, 56.79%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 46 people, 56.79%
Dizziness: 46 people, 56.79%
Conjunctivitis (pink eye): 46 people, 56.79%

What are the existing conditions these people have? *

Asthma: 71 people, 87.65%
Urticaria (rash of round, red welts on the skin that itch intensely): 29 people, 35.80%
Hypersensitivity: 11 people, 13.58%
Pain: 8 people, 9.88%
Multiple Allergies (allergy to multiple agents): 5 people, 6.17%
Indigestion: 2 people, 2.47%
Diarrhea: 2 people, 2.47%
Migraine (headache): 1 person, 1.23%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 1 person, 1.23%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 1.23%

* Approximation only. Some reports may have incomplete information.

Do you take Nucala and have Hyperventilation?

- Check whether Hyperventilation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nucala:

Nucala (26,883 reports)

Browse all side effects of Nucala:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperventilation:

Hyperventilation (846 drugs)

Browse all the conditions that are associated with Hyperventilation:

Hyperventilation (1,433 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mepolizumab (the active ingredients of Nucala) and Nucala (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.